Valuation: Spyre Therapeutics, Inc.

Market Cap 9.06B 7.85B 7.35B 6.71B 12.62B 864B 12.83B 86.18B 33.76B 432B 34.01B 33.27B 1,443B P/E 2026 *
-35.6x
P/E 2027 * -29x
Enterprise Value 8.6B 7.46B 6.98B 6.37B 11.98B 821B 12.19B 81.84B 32.07B 411B 32.3B 31.6B 1,370B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.36%
Yield 2026 *
-
Yield 2027 * -
1 day-2.46%
1 week-2.10%
Current month+4.48%
1 month+5.12%
3 months+34.42%
6 months+202.89%
Current year+213.61%
1 week 99.84
Extreme 99.84
107
1 month 92.37
Extreme 92.37
108.14
Current year 28
Extreme 28
108.14
1 year 14.5
Extreme 14.505
108.14
3 years 8.43
Extreme 8.43
108.14
5 years 2.66
Extreme 2.66
212.5
10 years 2.66
Extreme 2.66
300
Manager TitleAgeSince
Chief Executive Officer 36 2023-11-26
Director of Finance/CFO 49 2023-08-31
Chief Tech/Sci/R&D Officer - 2023-11-26
Director TitleAgeSince
Director/Board Member 36 2023-11-26
Director/Board Member 39 2023-06-21
Director/Board Member 36 2023-06-21
Date Insider Type Main position Quantity % Market Cap.
8/7/26
Sessions LLC
SellCompany -18,000 0.0207%
8/7/26 Fiscal year

Chairman

15,000 0.0173%
8/3/26 Fiscal year

Chief Financial Officer

22,500 0.0259%
Change 5-day change 1-year change 3-year change Capi.($)
-2.46%-2.10%+573.70%+721.92% 9.06B
-0.70%+13.34%+75.61%+103.83% 70.51B
-0.24%-0.19%+35.26%+63.47% 54.05B
-1.62%+34.25%+17.43%+491.04% 28.95B
-0.61%+12.51%+54.60%+7.40% 24.05B
0.00%+1.59%-15.06%-13.21% 23.31B
+9.77%+20.16%+260.17%+472.38% 18.67B
-0.43%+4.94%+43.46%-21.68% 18.37B
0.00%+7.46%+30.95%+623.97% 16.1B
-3.08%-8.34%+37.21%+138.52% 12.72B
Average +0.06%+366.43%+111.33%+258.76% 27.58B
Weighted average by Cap. -0.04%+342.06%+74.43%+187.12%

Financials

2026 *2027 *
Net sales - -
Net income -258M -224M -209M -191M -360M -24.63B -366M -2.46B -962M -12.33B -970M -948M -41.13B -327M -283M -265M -242M -455M -31.16B -463M -3.11B -1.22B -15.6B -1.23B -1.2B -52.04B
Net Debt -456M -395M -370M -337M -635M -43.46B -645M -4.33B -1.7B -21.75B -1.71B -1.67B -72.56B -565M -490M -458M -418M -787M -53.89B -800M -5.38B -2.11B -26.98B -2.12B -2.08B -89.99B
Logo Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).
Employees
125
Date Price Change Volume
26-08-11 US$102.74 -2.46% 931,734
26-08-10 US$105.33 +0.40% 822,714
26-08-07 US$104.91 +1.44% 526,596
26-08-06 US$103.42 -0.89% 454,482
26-08-05 US$104.35 -0.56% 1,037,497
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
102.74USD
Average target price
122.14USD
Spread / Average Target
+18.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SYRE Stock